• 1
    Longeri M, Ferrari P, Knafelz P, et al. Myosin-binding protein C DNA variants in domestic cats (A31P, A74T, R820W) and their association with hypertrophic cardiomyopathy. J Vet Intern Med 2013;27:275285.
  • 2
    Meurs KM, Norgard MM, Kuan M, et al. Analysis of 8 sarcomeric candidate genes for feline hyypertorphic cardiomyopathy mutations in cats with hypertrophic cardiomyopathy. J Vet Intern Med 2009;23:840843.
  • 3
    Meurs KM, Norgard MM, Ederer MM, et al. A substitution mutation in the myosin binding protein C gene in Ragdoll hypertrophic cardiomyopathy. Genomics 2007;90:261264.
  • 4
    Abbott JA. Feline hypertrophic cardiomyopathy: An update. Vet Clin Small Anim 2010;40:687700.
  • 5
    Kittleson MD, Meurs KM, Munro MJ, et al. Familial hypertrophic cardiomyopathy in Maine Coon cats: An animal model of human disease. Circulation 1999;99:31723180.
  • 6
    Virchow R. Neuer Fall von toedlicher Embolie der Lungenarterien. Arch Pathol Anat 1856;10:225229.
  • 7
    Liu SK. Acquired cardiac lesions leading to congestive heart failure in the cat. Am J Vet Res 1971;31:20712088.
  • 8
    Schober KE, Maerz M. Assessment of left atrial appendage flow velocity and its relationship to spontaneous echocardiographic contrast in 89 cats with myocardial disease. J Vet Intern Med 2006;20:120130.
  • 9
    MacDonald KA, Kittleson MD, Garcia-Nolan T, et al. Tissue Doppler imaging and graduate echo cardiac magnetic resonance imaging in normal cats and cats with hypertrophic cardiomyopathy. J Vet Intern Med 2006;20:627634.
  • 10
    Cambronero F, Marin F, Roldan V, et al. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: Implications for clinical management and prognosis. Eur Heart J 2009;30:139151.
  • 11
    Riazanov AS, Gabbasov ZA, Iurenev AP. Platelet aggregation in patients with hypertrophic cardiomyopathy. Ter Arkh 2000;72:3638.
  • 12
    Icli A, Aksoy F, Dogan A, et al. Increased mean platelet volume in hypertrophic cardiomyopathy. Angiology 2013 Apr 5 (Epub ahead of print)
  • 13
    Yarom R, Lewis BS, Lijovetsky G, et al. Platelet studies in patients with hypertrophic cardiomyopathy. Cardiovasc Res 1982;16:324330.
  • 14
    Weikert U, Kuhl U, Schultheiss HP, Tauch U. Platelet activation is increased in patients with cardiomyopathy: Myocardial inflammation and platelet reactivity. Platelets 2002;13:487491.
  • 15
    Tse H-F, Lau C-P, Cheng G. Relation between mitral regurgitation and platelet activation. J Am Coll Cardiol 1997;30:18131818.
  • 16
    Nesbitt WS, Weinstein E, Tovar-Lopez FJ, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009;15:665673.
  • 17
    Holme PA, Orvim U, Hamers MJ, et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997;17:646653.
  • 18
    Bedard C, Lanevschi-Pietersma A, Dunn M. Evaluation of coagulation markers in the plasma of healthy cats and cats with asymptomatic hypertrophic cardiomyopathy. Vet Clin Pathol 2007;36:7984.
  • 19
    Helenski CA, Ross JN. Platelet aggregation in feline cardiomyopathy. J Vet Internal Med 1987;1:2428.
  • 20
    Welles EG, Boudreau MK, Crager CS, et al. Platelet function and anti-thrombin, plasminogen and fibrinolytic activities in cats with heart disease. Am J Vet Res 1994;55:619627.
  • 21
    Hsu A, Kittleson MD, Paling A. Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy. J Vet Cardiol 2009;S1:S63S70.
  • 22
    Robert S, Poncelet P, Lacroix R, et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: A first step towards multicenter studies? J Thromb Haemostasis 2008;7:190197.
  • 23
    Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957;17:237246.
  • 24
    Norris JW, Pratt SM, Hunter JF, et al. Prevalence of reduced fibrinogen binding to platelets in a population of Thoroughbreds. Am J Vet Res 2007;68:716721.
  • 25
    Norris JW, Pratt SM, Auh JH, et al. Investigation of a novel, heritable bleeding diathesis of Thoroughbred horses and development of a screening assay. J Vet Intern Med 2006;20:14501456.
  • 26
    Ramstrom AS, Fagerberg I, Lindahl T. A flow cytometric assay for the study of dense granule storage and release in human platelets. Platelets 1999;2:153158.
  • 27
    Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000;102:19311936.
  • 28
    Lehr HA, Olofsson AM, Carew TE, et al. P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo. Lab Invest 1994;71:380386.
  • 29
    Kirton CM, Nash GB. Activated platelets adherent to an intact endothelial cell monolayer bind flowing neutrophils and enable them to transfer to the endothelial surface. J Lab Clin Med 2000;136:303313.
  • 30
    Isenberg WM, McEver RP, Shuman MA, Bainton DF. Topographic distribution of a granule membrane protein (GMP-140) that is expressed on the platelet surface after activation: An immunogold-surface replica study. Blood Cells 1994;12:191204.
  • 31
    Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992;359:848851.
  • 32
    Mayadas TN, Johnson RC, Rayburn H, et al. Leukocyte rolling and extravasation are severely compromised in P-selectin deficient mice. Cell 1993;13:541554.
  • 33
    Cambien B, Wagner DD. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med 2004;10:179186.
  • 34
    Patil S, Newman DK, Newman PJ. Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen. Blood 2001;97:17271732.
  • 35
    Serebruany VL, Murugesan SR, Pothula A, et al. Increased soluble platelet-endothelial cell adhesion molecule -1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. Eur J Heart Failure 1999;1:243249.
  • 36
    Serebruany VL, Murugesan SR, Pothula A, et al. Soluble PECAM-1, but not P-selectin nor osteonectin identify acute myocardial infarction in patients presenting with chest pain. Cardiology 1999;91:5055.
  • 37
    Privratsky JR, Newman DK, Newman PJ. PECAM-1: Conflicts of interest in inflammation. Life Sci 2010;87:6982.
  • 38
    Zhang JJ, Kelm RJ, Biswas P, et al. PECAM-1 modulates thrombin-induced tissue factor expression on endothelial cells. J Cell Physiol 2007;210:527537.
  • 39
    Ming Z, Hu Y, Xiang J, et al. Lyn and PECAM-1 function as interdependent inhibitors of platelet aggregation. Blood 2011;117:39033906.
  • 40
    Soeki T, Yamura Y, Shinohara H, et al. Increased soluble platelet/endothelial cell adhesion molecule-1 in the early stages of acute coronary syndromes. Int J Cardiol 2003;90:261268.
  • 41
    Hogye M, Mandi Y, Csanady M, et al. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrohic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol 2004;94:249251.